GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Aarey Drugs and Pharmaceuticals AAREYDRUGS.NS · INR

Health Care · NSE · 🇮🇳 India

Compare

109.04

+1.23%

Close of 9 Nov 2026, in INR

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in INR, from our data supplier.

FY2026

Revenue

₹4.72bn

FY2017FY2026

Net income

₹39.7m

FY2017FY2026

Free cash flow

−₹233.9m

FY2017FY2026

Shareholders' equity

₹1.50bn

FY2017FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue₹4.72bn₹4.74bn₹3.95bn₹4.19bn₹4.92bn₹3.48bn₹3.00bn₹3.55bn₹3.49bn₹3.96bn
Gross profit₹141.5m₹91.3m₹132.0m₹115.1m₹195.4m₹136.4m₹99.1m₹137.3m₹112.7m₹117.4m
Operating income₹93.2m₹43.2m₹97.2m₹94.6m₹117.7m₹107.4m₹23.6m₹70.5m₹72.8m₹90.3m
Net income₹39.7m₹40.2m₹46.8m₹37.7m₹65.5m₹65.1m₹57.9m₹65.4m₹61.8m₹54.7m
Diluted earnings per share1.401.411.671.492.582.572.482.802.642.73

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assets₹2.97bn₹2.38bn₹3.03bn₹2.91bn₹2.45bn₹2.33bn₹1.94bn₹1.46bn₹1.70bn₹1.43bn
Cash and short-term investments₹34.0m₹32.3m₹28.9m₹11.2m₹1.9m₹6.5m₹5.0m₹3.7m₹33.9m₹10.4m
Total liabilities₹1.47bn₹997.9m₹1.71bn₹1.74bn₹1.32bn₹1.34bn₹1.02bn₹591.6m₹895.5m₹929.1m
Debt₹499.6m₹348.6m₹313.5m₹377.2m₹141.6m₹180.2m₹178.9m₹161.6m₹32.4m₹103.9m
Shareholders' equity₹1.50bn₹1.38bn₹1.33bn₹1.17bn₹1.14bn₹988.6m₹923.5m₹865.5m₹802.4m₹503.6m
Shares outstanding28m28m28m25m25m25m23m23m23m20m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations−₹109.8m₹8.9m−₹29.9m−₹12.8m₹5.0m₹54.8m₹28.6m₹6.9m−₹203.5m₹9.6m
Capital spending−₹124.1m−₹52.0m−₹7.2m−₹10.4m−₹22.0m−₹28.8m−₹9.2m−₹12.3m−₹6.2m−₹49.4m
Free cash flow−₹233.9m−₹43.1m−₹37.2m−₹23.3m−₹17.0m₹26.0m₹19.4m−₹5.4m−₹209.7m−₹39.7m
Dividends paid———————−₹2.3m−₹2.3m—

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue₹446.3m₹1.89bn₹964.3m₹841.6m₹1.02bn₹1.08bn₹1.34bn₹1.05bn
Gross profit₹14.6m₹89.4m−₹13.4m₹28.0m₹43.7m₹757,999₹34.0m₹62.4m
Operating income₹4.8m₹34.9m−₹23.4m₹19.5m₹27.7m₹22.8m₹16.2m₹32.3m
Net income₹10.2m₹15.6m₹5.7m₹10.2m₹13.7m₹4.7m₹7.2m₹16.0m
Diluted earnings per share0.360.550.200.360.480.170.260.57
Cash from operations———₹145.0m————
Capital spending———−₹100.0m————
Free cash flow———₹45.0m————
Total assets—₹2.97bn—₹2.94bn—₹2.38bn—₹2.75bn
Cash and short-term investments₹34.0m₹34.0m₹81.9m₹81.9m₹32.3m₹14.7m₹14.9m₹14.9m
Debt—₹499.6m—₹507.8m—₹348.6m—₹386.5m
Shareholders' equity₹1.50bn₹1.50bn₹1.49bn₹1.49bn₹1.38bn₹1.38bn₹1.36bn₹1.36bn

Financial ratios

Data as of 31 Oct 2026

FY2026FY2025FY2024FY2023FY2022FY2021
Gross margin3.0%1.9%3.3%2.7%4.0%3.9%
Operating margin2.2%2.1%2.5%2.1%2.5%3.1%
Net margin0.8%0.8%1.2%0.9%1.3%1.9%
Return on equity2.6%2.9%3.5%3.2%5.8%6.6%
Return on assets1.3%1.7%1.5%1.3%2.7%2.8%
Free cash flow yield0.5%2.0%-0.8%-0.1%1.0%3.1%
Revenue growth-0.4%20.0%-5.7%-14.8%41.3%15.9%
Earnings growth-1.4%-14.1%24.2%-42.5%0.6%12.4%
Current ratio1.81x2.20x1.70x1.61x1.73x1.67x
Debt to equity0.33x0.25x0.24x0.32x0.12x0.18x
Equity ratio50.6%58.1%43.8%40.3%46.4%42.4%
Interest coverage2.08x2.52x2.22x3.10x5.93x4.40x
Buybacks as a share of market value0.1%-1.4%-10.5%0.0%0.0%-8.6%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue4.1%6.3%6.7%
Operating income-0.5%-2.8%37.2%
Net income1.7%-9.4%11.9%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin2.5%2.7%3.1%3.1%
Operating margin1.4%1.9%2.1%1.9%
Net margin0.8%0.9%1.1%1.3%

Valuation history

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021
Price to earnings78.047.934.234.015.016.7
Price to sales0.70.40.40.30.20.3

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.